Clinical Trial

Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The Phase Ib stage of this study primarily aims to evaluate the tolerance and safety of TQB6411 Injection in participants with recurrent or metastatic Esophageal cancer who have previously failed treatment with PD-1/PD-L1 monoclonal antibodies combined with platinum-based chemotherapy. The Phase II stage primarily aims to evaluate the efficacy of TQB6411 Injection in this same participants population.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-01-18; most recent amendment 2026-06-30.
Status change: Not Yet Recruiting → Recruiting 2026-03-03
Trial Details
NCT Number NCT07367516
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Esophageal Cancer
Enrollment 105 participants
Start Date 2026-02-12
Primary Completion 2026-09 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-02